Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- GLPG.AS
- Price
- 23.82
- Stock movement down
- -0.14 (-0.58%)
- Company name
- Galapagos N.V.
- Exchange
- (AS ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 1.57B
- Ent værdi
- 2.82B
- Pris/omsætning
- -
- Pris/bog
- 0.55
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -
- Efterfølgende P/E
- 7.61
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -
- 1 års afkast
- -0.92%
- 3 års afkast
- -24.88%
- 5 års afkast
- -33.16%
- 10 års afkast
- -8.60%
Senest opdateret: 2025-06-22
UDBYTTE
GLPG.AS betaler ikke udbytte
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | 7.61 |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | - |
| Pris til egenkapital | 0.55 |
| EV i forhold til salg | -314.80 |
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 65.90M |
| EPS (TTM) | 3.13 |
| FCF pr. aktie (TTM) | -6.25 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | -8.97M |
| Bruttofortjeneste (TTM) | -112.52M |
| Driftsindkomst (TTM) | -194.93M |
| Nettoindkomst (TTM) | 206.33M |
| EPS (TTM) | 3.13 |
| EPS (1 år frem) | -0.70 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 1254.40% |
| Driftsmargin (TTM) | 2173.09% |
| Fortjenstmargin (TTM) | -2300.27% |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 55.52M |
| Nettotilgodehavender | 45.43M |
| Omsætningsaktiver i alt | 3.56B |
| Goodwill | 69.47M |
| Immaterielle aktiver | 173.43M |
| Ejendomme, anlæg og udstyr | 0.00 |
| Sum aktiver | 4.17B |
| Kreditor | 115.86M |
| Kortfristet/nuværende langsigtet gæld | 0.00 |
| Summen af kortfristede forpligtelser | 351.23M |
| Sum gæld | 1.31B |
| Aktionærernes egenkapital | 2.86B |
| Materielle nettoaktiver | 0.00 |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | -327.52M |
| Investeringsudgifter (TTM) | 84.39M |
| Fri pengestrøm (TTM) | -411.91M |
| Udbetalt udbytte (TTM) | 0.00 |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | 7.21% |
| Afkast af aktiver | 4.95% |
| Afkast af investeret kapital | 7.21% |
| Kontant afkast af investeret kapital | -14.39% |
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 24.06 |
| Daglig høj | 24.68 |
| Daglig lav | 23.70 |
| Daglig volumen | 115K |
| Højeste gennem alle tider | 249.50 |
| 1 års analytiker estimat | 36.50 |
| Beta | 0.06 |
| EPS (TTM) | 3.13 |
| Udbytte pr. aktie | - |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | - |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| GLPG.AS | S&P500 | |
| Nuværende prisfald fra top notering | -90.45% | -3.04% |
| Højeste prisfald | -91.58% | -56.47% |
| Højeste efterår dato | 7 Apr 2025 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -35.42% | -11.04% |
| Gennemsnitlig tid til nyt højdepunkt | 28 days | 12 days |
| Maks. tid til nyt højdepunkt | 1366 days | 1805 days |
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
1.57B
Markedsværdi kategori
Small-cap
Beskrivelse
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Personale
1123
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
Netherlands
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership Mechelen, Belgium; June 23, 2025, 07:30 CET; regulated inf...
23. juni 2025
Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase 1/2 study, 32 received GLPG5101; 94% were infused with fresh CAR-T cells, and 93% were treated within seven days of manufacturing GLPG51...
18. juni 2025
Key Insights Given the large stake in the stock by institutions, Galapagos' stock price might be vulnerable to their...
17. juni 2025
Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-Hodgkin’s Lymphoma (R/R NHL) patient population demonstrate low rates of high-grade toxicities...
12. juni 2025
Mechelen, Belgium; May 27, 2025, 22:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 925,000 subscription rights under a new s...
27. maj 2025
Mechelen, Belgium; May 14, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovati...
14. maj 2025
Galapagos to re-evaluate the implementation of the previously announced separation following regulatory and market developments Galapagos to explore all strategic alternatives for its existing busines...
13. maj 2025
Galapagos ( AMS:GLPG ) First Quarter 2025 Results Key Financial Results Revenue: €75.0m (up 20% from 1Q 2024). Net...
26. april 2025
First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal developme...
23. april 2025
Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as founding CEO of newly created SpinCo Dr. Paul Stoffels, Chair and CEO of Galapagos, plans to retire as CEO upon appointment of succ...
21. april 2025
Næste side